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Abstract: Background and objectives: Cardiovascular (CV) disease is a major cause of morbidity and 
mortality in chronic obstructive pulmonary disease (COPD). Patients with COPD have increased 
arterial stiffness, which may predict future CV risk. However, the development of arterial stiffness 
in COPD has not yet been studied prospectively. The Assessment of Risk in Chronic Airways 
Disease Evaluation (ARCADE) is a longitudinal study of CV risk and other comorbidities in COPD. 
The aims of this analysis were to explore factors associated with aortic pulse wave velocity (aPWV) 
at baseline and to describe the progression of aPWV in patients with COPD and comparators over 
two years. Materials and methods: At baseline, 520 patients with COPD (confirmed by spirometry) 
and 150 comparators free from respiratory disease were assessed for body composition, blood 
pressure, aPWV, noninvasive measures of cardiac output, inflammatory biomarkers, and exercise 
capacity. This was repeated after two years, and mortality cases and causes were also recorded. 
Results: At baseline, aPWV was greater in COPD patients 9.8 (95% confidence interval (CI) 9.7–10.0) 
versus comparators 8.7 (8.5–9.1) m/s (p < 0.01) after adjustments for age, mean arterial pressure 
(MAP), and heart rate. Mean blood pressure was 98 ± 11 in COPD patients and 95 ± 10 mmHg in 
comparators at baseline (p = 0.004). After two years, 301 patients and 105 comparators were fully 
reassessed. The mean (95% CI) aPWV increased similarly in patients 0.44 (0.25–0.63) and 
comparators 0.46 (0.23–0.69) m/s, without a change in blood pressure. At the two-year follow-up, 
there were 29 (6%) deaths in COPD patients, with the majority due to respiratory causes, with an 
overall dropout of 43% of patients with COPD and 30% of comparators. Conclusions: This was the 
first large longitudinal study of CV risk in COPD patients, and we confirmed greater aPWV in 
COPD patients than comparators after adjustments for confounding factors. After two years, 
patients and comparators had a similar increase of almost 0.5 m/s aPWV. 
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1. Introduction 
Chronic obstructive pulmonary disease (COPD) is now the third leading cause of mortality 
worldwide [1]. Although many associate COPD mainly with a progressive decline in lung function, 
this disease should be actually regarded as a multisystem disorder with major extrapulmonary 
complications and comorbidities. These include increased cardiovascular (CV) risk, loss of skeletal 
muscle mass and function, decreased exercise capacity, the development of osteoporosis, insulin 
resistance, and diabetes mellitus [2–6]. 
Cardiovascular disease is a major cause of mortality, accounting for 30%–50% of deaths in 
COPD, independent of cigarette smoking status [7]. Aortic stiffness is an independent predictor of 
CV morbidity and mortality in general and diseased populations and has been related to a decline in 
the forced expiratory volume in one second (FEV1) [8,9]. It has been suggested that increased arterial 
stiffness causes premature vascular aging and contributes to excess CV disease in COPD [10]. 
Increased aortic stiffness occurs with mid-to-late central systolic pressure and leads to increasing left 
ventricular afterload and myocardial oxygen demand, while reducing diastolic pressure 
augmentation of myocardial perfusion and increasing the risk of ischemia and ventricular 
dysfunction. A cross-sectional population study has confirmed greater aortic pulse wave velocity 
(aPWV) in COPD using a Vicorder device, which was associated with reported CV disease but did 
not report or adjust for blood pressure [11]. These changes can present regardless of the severity of 
airflow limitation from COPD [12]. Aortic pulse wave velocity is a reliable measure of aortic stiffness 
and is increased in COPD [13]. Nevertheless, to date, no measure of arterial stiffness has been 
validated as a prognostic CV risk predictor in COPD. 
The mechanism of CV risk in COPD has not been fully established, although there have been a 
number of suggestions for the development of increased arterial stiffness. Chronic systemic 
inflammation, increased insulin resistance, the risk of developing diabetes mellitus [3,6], as well as 
low fat-free mass and bone mineral density have been related to aortic stiffness in COPD in cross-
sectional studies [10]. 
The progression of aPWV in COPD has not yet been studied prospectively: Such studies may 
help to elucidate the mechanism of CV risk. The Assessment of Risk in Chronic Airways Disease 
Evaluation (ARCADE) is a longitudinal study of CV risk and other comorbidities in COPD [13]. The 
primary aims are to delineate the progression and inter-relationships of CV disease and associated 
comorbidities. The aims of this analysis were to explore factors associated with aPWV at baseline and 
to describe the progression of aortic pulse wave velocity in patients with COPD and comparators 
over two years. 
Clinical Vignette 
Progression of COPD: The following is a clinical vignette based on a patient recruited to the 
ARCADE study. 
A 69-year-old male past smoker with a pack history of 40 pack years presented with mild 
breathlessness walking uphill (modified Medical Research Council (mMRC) 1). 
Baseline assessments were as follows: 
 Spirometry: FEV1 2.15, forced vital capacity (FVC) 4.4, FEV1:FVC 0.49 (L). FEV1 percent of 
predicted 67%; 
 Clinical measures: BMI 27.7 kg/m2, 6-min walk distance 450 m, high sensitivity c-reactive protein 
(HsCRP) 1.6 mg/L; 
 Cardiovascular measures: Blood pressure 133/78 mmHg, aortic PWV 8.9 m/s. 
After two years, the assessments were as follows: 
 Spirometry: FEV1 1.97, FVC 3.8, FEV1:FVC 0.52 (L). FEV1 percent of predicted 63%; 
 Clinical measures: BMI 30.4 kg/m2, 6-min walk distance 405 m, HsCRP 1.5 mg/L; 
 Cardiovascular measures: Blood pressure 137/82 mmHg, aortic PWV 9.4 m/s. 
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This case study describes a patient who was relatively clinically stable, with a small decline in 
lung function after two years. Despite a small change in blood pressure, which remained 
normotensive, there was an increase in aortic PWV of 0.5 m/s, indicating greater arterial stiffness and 
increased cardiovascular risk. 
2. Materials and Methods 
2.1. Design and Participants 
The ARCADE is a prospective longitudinal observational study of patients with prior physician-
diagnosed COPD and comparators undertaken in Cardiff, U.K. (NCT 01656421). The study was 
conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines and 
was approved by the South East Wales Ethics Committee, which is part of the National Research 
Ethics Service (U.K.). 
Patients had COPD, confirmed by postbronchodilator spirometry, and were clinically stable (at 
least four weeks from exacerbation). Patients with other inflammatory disease or on long-term 
oxygen therapy were excluded to avoid the known cardiovascular complications and possible effects 
on the arterial wall and amplification of cardiovascular risk. Comparators were current or past 
smokers with a spirometry of FEV1/FVC > 0.7. All participants were aged 35–80 years at baseline and 
continued to receive their regular prescribed medications throughout the study. 
Recruitment sources included general practice databases, respiratory outpatient clinics, 
pulmonary rehabilitation and smoking cessation referrals, and previous participants in respiratory 
research at Cardiff University. Participants were assessed at baseline and after two years. The 
recruitment and follow-up of participants is illustrated in Figure 1. 
 
Figure 1. Flow diagram of recruitment and follow-up of participants. * Chronic obstructive 
pulmonary disease (COPD) exclusions: Cancer (n = 16), long-term oxygen therapy (n = 4), dementia 
(n = 1); ~COPD withdrawn: Unwell and unable to attend the second visit; ** comparator exclusions: 
Cancer (n = 15), respiratory disease (n = 5), aortic aneurism (n = 1), myocardial infarction (n = 1). 
2.2. Data Collection 
The following outcome measures were completed at baseline and repeated after two years, 
where possible. Mortality data including cause of death were collected from the National Health 
ARCADE
COPD Baseline
n = 520
2 year follow-up
n = 320
Death (29)
Declined (n = 37)
Excluded* (n = 21)
Withdrawn~ (n = 30)
Unavailable (n = 83)
Comparator
n = 150
2 year follow-up
n = 107
Death (n = 2)
Excluded** (n = 22)
Declined (n = 4)
Unavailable (n = 15)
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Service (NHS) Information Service Centre. The full methods, including the determination of 
acceptable reproducibility of haemodynamic measures, have been published [13]. The following 
assessments were included in the current analysis. 
2.3. Anthropometry and Pulmonary Function 
Height and weight were determined barefoot and used to calculate body mass index (BMI). A 
postbronchodilator spirometry was performed after inhalation of salbutamol (200 μg) (Vitalograph, 
Buckingham, U.K.). Forced expiratory volume (FEV1), forced vital capacity (FVC), and their ratio 
(FEV1/FVC) were noted [14]. 
Patients completed a questionnaire that included medical and smoking history, modified 
medical research council (mMRC) breathlessness and number of exacerbations per year. 
2.4. Physical Performance 
Six-minute walking distance (6-MWD) with pre- and post-test resting heart rate (HR) and 
oxygen saturation (SaO2%) were recorded by pulse oximetry according to guidelines [15]. 
2.5. Cardiovascular Measurements 
After 10 min of rest, seated and supine peripheral systolic and diastolic blood pressure (BP) were 
determined (OMRON Corporation, Kyoto, Japan). Arterial waveforms were recorded with a high-
fidelity micromanometer (SPC-301, Millar Instruments, Houston, TX, USA). A corresponding central 
(aortic) waveform was generated using the SphygmoCor system (AtCor Medical, Sydney, Australia) 
[16]. Central systolic and diastolic pressure and mean arterial pressure were calculated from the 
central aortic waveform. The pulse wave velocity (PWV) was measured using the same device by 
sequentially recording electrocardiogram-gated carotid and femoral artery waveforms (aortic PWV). 
Cardiac output, stroke volume, and cardiac index were non-invasively determined using a chest 
bioreactance technique (Non-Invasive Cardiac Output Monitoring (NICOM™) (Cheetah Medical, 
Wilmington, DE, U.S.)) [17]. 
2.6. Blood Biochemistry 
Venous blood was obtained to determine systemic inflammation (fibrinogen and high-
sensitivity c-reactive protein (Hs-CRP) in the Cardiff and Vale University Hospital biochemistry 
laboratory according to standard procedures. Fibrinogen was included because of its value in 
identifying high-risk COPD patients both in clinical practice and due to its association with 
phenotypes in COPD [18]. Hs-CRP was chosen given its prognostic value in cardiovascular disease 
[19]. 
2.7. Statistical Analysis 
Clinical and demographic data were expressed as mean ± SD or median (interquartile range 
(IQR)) for nonparametric data. The baseline parametric analysis included an independent t-test, with 
the Mann–Whitney U test and chi-square test being used for nonparametric data. Where appropriate, 
positively skewed data were log10-transformed for analysis and expressed as geometric mean ± SD. 
Baseline aPWV was additionally adjusted for age, mean arterial pressure (MAP), and HR using 
analysis of covariance when comparing aPWV between COPD patients and comparators. Univariable 
linear regression models were fitted to identify factors associated with aPWV. Explanatory variables 
with a p-value ≤ 0.15 and not highly correlated with another variable of interest were used to build a 
stepwise multivariable model, and aPWV was log-transformed in order to fulfill the model 
assumption of linearity. Longitudinal data were analyzed using repeated measures ANOVA, with 
differences in baseline and two-year follow-up measurements expressed as the mean (95% confidence 
interval (CI)). The analysis was undertaken using the statistical software package SPSS 20.0 (Chicago, 
IL, U.S.). 
Medicina 2019, 55, 89 5 of 13 
3. Results 
3.1. Demographics of Baseline Recruitment 
At baseline, 520 patients with COPD and 150 comparators were assessed. Patients with COPD 
and comparators were similar in age, gender, and BMI (Table 1). However, COPD patients had a 
greater smoking history, and there were more current smokers than in the comparators (p < 0.05). 
COPD patients had poorer lung function according to spirometry and lower 6-MWDs and resting 
SaO2 than comparators (p < 0.05) (Table 1). The majority of patients had moderate to severe disease 
according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) categories: GOLD 1 (n 
= 70), GOLD 2 (n = 269), GOLD 3 (n = 146), GOLD 4 (n = 35) [20]. 
Table 1. Baseline characteristics of patients with COPD and comparators. 
 COPD, n = 520 Comparators, n = 150 p-Value 
Age (years) 66.1 ± 7.6 65.0 ± 7.4 0.109 
Gender, male/female, n 270:250 76:74 0.786 
BMI (Kg/m2) 28.0 ± 5.5 28.1 ± 4.1 0.942 
FEV1 (L) 1.42 ± 0.60 2.74 ± 0.68 <0.001 
FVC (L) 2.67 ± 0.90 3.53 ± 0.90 <0.001 
FEV1/FVC (L) 0.53 ± 0.11 0.78 ± 0.05 <0.001 
FEV1 (% of predicted) 58 ± 19 105 ± 14 <0.001 
FVC (% of predicted) 87 ± 21 109 ± 15 <0.001 
Smoking (pack years) 40 ± 26 21 ± 18 <0.001 
Current smokers, n (%) 183 (35%) 26 (17%) <0.001 
mMRC (median (IQR)) 2 [1–3] - - 
No. Exac/Yr (median [IQR]) 2 [1–3] - - 
Resting O2 (%) 97 ± 2 98 ± 1 <0.001 
6-MWD (m) 335 ± 125 502 ± 86 <0.001 
aPWV (m/s) 10.0 ± 2.4 8.4 ± 1.8 <0.001 
Peripheral SBP (mmHg) 146 ± 18 140 ± 18 <0.001 
Peripheral DBP (mmHg) 82 ± 10 81 ± 9 0.{Patel, 2006 #110}3 
Peripheral PP (mmHg) 64 ± 16 60 ± 15 0.001 
Central SBP (mmHg) 127 ± 17 123 ± 16 0.020 
Central DBP (mmHg) 77 ± 10 74 ± 9 0.005 
Central PP (mmHg) 50 ± 13 49 ± 12 0.335 
Central MAP (mmHg) 98 ± 11 95 ± 10 0.004 
Heart rate (bpm) 74 ± 11 67 ± 11 <0.001 
Cardiac output (L/min) 5.8 ± 1.2 6.0 ± 1.1 0.165 
Cardiac index (L/min/m2) 3.2 ± 0.5 3.2 ± 0.5 0.864 
Stroke volume (mLs) 86 ± 20 96 ± 20 <0.001 
Fibrinogen (g/L) # 3.5 {3.4, 3.6} 3.1 ± {2.9, 3.2} <0.001 
HsCRP (mg/L) # 3.4 {3.1, 3.8} 1.7 ± {1.4, 2.1} <0.001 
Data are mean ± SD unless stated; # geometric mean (95% confidence interval); p < 0.05, significant 
difference between groups; aPWV = aortic pulse wave velocity; 6-MWD = six-minute walk distance; 
BMI = body mass index; FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity; HsCRP 
= high sensitivity c-reactive protein; mMRC = modified medical research council breathlessness; IQR 
= interquartile range; SBP = systolic blood pressure; DBP = diastolic blood pressure; PP = pulse 
pressure; MAP = mean arterial pressure. 
Patients with COPD had a greater aPWV, peripheral systolic BP, central systolic and diastolic 
BP, MAP, and heart rate, and had a lower stroke volume (p < 0.01), than comparators. Inflammation 
(fibrinogen and HsCRP) was also greater in COPD patients. The greater aPWV in COPD patients 
remained after adjustments for age, MAP, and heart rate: COPD patients 9.8 (95% CI 9.7–10.0) versus 
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comparator 8.7 (8.5–9.1) m/s (p < 0.01). The aPWV was greater in patients than for comparators in 
each age decade (<49 years excluded due to small numbers) (p < 0.05) (Figure 2). 
 
Figure 2. Mean (standard deviation) aPWV in patients with COPD and comparators across each 
decade. ** = p < 0.001 significant difference between groups; note: age <49 excluded due to small 
numbers. 
3.2. Medical History 
Patients with COPD reported more comorbidities: Hypertension and hypercholesterolemia 
were more frequent in COPD patients than in comparators (Table 2). A total of 84% (n = 437) of COPD 
patients reported one or more comorbidities, compared to 66% (n = 89) of comparators (p < 0.05). 
Patients were also prescribed more medications than comparators (p < 0.05) (Table 2). In the patient 
group, inhaled therapy comprised short-acting β2-agonists (n = 320), long-acting β-agonists (LABA) 
(n = 31), long-acting muscarinic antagonists (n = 305), inhaled corticosteroids (ICS) alone (n = 29), 
combination (ICS & LABA) (n = 275), anticholinergics (n = 12), and methylxanthines n = 15. None of 
the comparators received inhaled therapy. 
Table 2. Comorbidities and medications in patients with COPD and comparators. 
 COPD, n = 520 Comparators, n = 150 p-Value 
No. of comorbidities 3 [2–4] 2 [1–3] <0.001 
Hypertension 245 (47%) 34 (23%) <0.001 
Angina 61 (12%) 0 (0%) <0.001 
Myocardial Infarction 46 (9%) 0 (0%) 0.002 
Atrial Fibrillation 42 (8%) 5 (3%) 0.018 
Heart failure 19 (4%) 0 (0%) 0.025 
Other heart diseases $ 40 (8%) 4 (3%) 0.045 
Transient ischaemic attack 36 (7%) 2 (1%) 0.009 
Hypercholesterolemia 237 (46%) 41 (27%) <0.001 
Diabetes mellitus 67 (13%) 0 (0%) <0.001 
Osteoporosis 87 (17%) 9 (6%) 0.001 
Peripheral vascular disease 19 (4%) 3 (2%) 0.317 
Osteoarthritis 177 (34%) 40 (27%) 0.089 
No. of medications 5 [3–8] 2 [0–3] <0.001 
Angiotensin-converting enzyme inhibitors 115 (22%) 9 (6%) <0.001 
Angiotensin receptor blockers 44 (8%) 2 (1%) 0.002 
Calcium channel blockers 114 (22%) 8 (5%) <0.001 
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Beta blockers 42 (8%) 5 (3%) 0.047 
Diuretics 109 (21%) 11 (7%) <0.001 
Anticoagulants 27 (5%) 2 (1%) 0.041 
Statins 192 (37%) 27 (18%) <0.001 
Bisphosphonates 72 (14%) 5 (3%) <0.001 
Inhaler therapy 419 (81%) 0 (0%) <0.001 
Note: n (%) or median (IQR); - not assessed; p < 0.05 significant difference between groups; $, other 
heart disease = arrhythmia, enlarged heart, heart murmur, valve disease, or vessel disease; inhalers = 
bronchodilators, inhaled corticosteroids, or antimuscarinics, alone or in combination. 
3.2.1. Determinants of Aortic PWV 
In COPD patients, gender, age, FEV1/FVC, BMI, central MAP, HR, 6-MWD, SaO2, smoking 
status, and the number of comorbidities were related to aPWVlog10 (p < 0.15). After adjustment, among 
COPD patients, age, BMI, MAP, and the number of comorbidities were significantly associated with 
aPWVlog10 (p < 0.05). Similarly, among comparators, after adjustment, age, MAP, and HR were 
significantly associated with aPWVlog10 (Table 3). The back-transformed regression coefficient 
represents the proportional increase in aPWV for each unit change of the corresponding explanatory 
variable. For example, for COPD patients, for a 1-yr increase in age, aPWV increased by a factor of 
1.013, i.e., by 1.3%. 
Table 3. Factors associated with aPWVlog10 among COPD patients and comparators. 
 
Regression 
Coefficient, 
Beta (S.E.) 
Back-Transformed 
Regression Coefficient * 
p-Value 
COPD (n = 520)    
Age (years) 0.0055 (0.001) 1.013 <0.001 
Central MAP (mmHg) 0.0023 (0.000) 1.005 <0.001 
HR (bpm) 0.0020 (0.000) 1.005 <0.001 
BMI (Kg/m2) 0.0025 (0.001) 1.006 <0.001 
No. of comorbidities 0.0085 (0.003) 1.019 0.001 
Comparator (n = 150) 
Age (years) 0.0053 (0.001) 1.012 <0.001 
Central MAP (mmHg) 0.0025 (0.001) 1.006 <0.001 
HR (bpm) 0.0023 (0.001) 1.005 0.001 
BMI = body mass index; HR = heart rate; MAP = mean arterial pressure; S.E. = standard error; * back-
transformed regression coefficient was calculated by 10^ beta. 
3.3. Follow-Up Data 
At the two-year follow-up, 320 patients and 107 comparators returned for reassessment (Figure 
2). Complete CV datasets were available for 301 patients and 105 comparators. A comparison of 
participants that completed and did not complete the visit showed similar baseline characteristics 
(Supplementary Materials, Table S1). 
Patients and comparators had a slight decline in FEV1 (L) and FVC (L), but no change in 
FEV1/FVC or FEV1% predicted. Among COPD patients, there was a significant decline in the mean 
(95% CI) 6-MWD of 27 m (15–39 m), and a 12 m (3–27 m) decline among comparators (p < 0.05) (Table 
4). Both COPD patients and comparators had a similar increase in aPWV of almost 0.5 m/s over two 
years (p < 0.05), despite a mean decrease in peripheral systolic BP and no change in central MAP, 
cardiac output (CO), stroke volume (SV), or inflammatory markers. There was a variable pattern of 
change in other variables among patients with COPD: 64% had a decline in FEV1 (L), 56% had a 
decrease in 6-MWD, 58% had an increase in aPWV, and 42% had an increase in systolic and diastolic 
BP. 
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Table 4. Baseline and two-year follow-up lung function, haemodynamic data, and exercise capacity 
in COPD patients and comparators. 
 COPD (n = 301)  Comparators (n = 105) 
p-
Value 
 Baseline Two Years p = Baseline 
Two 
Years 
 
FEV1 (L) 1.41 ± 0.59 1.34 ± 0.60 <0.001 
2.73 ± 
0.69 
2.63 ± 0.69 <0.001 
FVC (L) 2.68 ± 0.88 2.49 ± 0.91 <0.001 
3.48 ± 
0.91 
3.37 ± 0.94 0.001 
FEV1 FVC (L) 0.52 ± 0.12 0.54 ± 0.13 0.001 
0.79 ± 
0.05 
0.78 ± 0.05 0.387 
FEV1 % 58 ± 19 57 ± 21 0.174 106 ± 14 104 ± 19 0.124 
SBP (mmHg) 147 ± 19 143 ± 19 <0.001 140 ± 18 137 ± 16 0.032 
DBP (mmHg) 82 ± 10 80 ± 10 <0.001 80 ± 9 80 ± 8 0.294 
Central MAP (mmHg) 98 ± 12 98 ± 11 0.208 95 ± 11 94 ± 11 0.775 
Aortic PWV (m/s) 10.0 ± 2.3 10.5 ± 2.6 <0.001 8.3 ± 1.7 8.8 ± 1.8 0.000 
Cardiac output (L/min)/# 5.8 ± 1.2 5.9 ± 1.3 0.084 5.9 ± 1.1 6.1 ± 1.4 0.109 
Cardiac index (L/min/m2) 
# 
3.2 ± 0.5 3.3 ± 0.6 0.005 3.1 ± 0.5 7.6 ± 39.5 0.250 
Stroke volume (mLs) # 87 ± 20 87± 22 0.882 95 ± 21 99 ± 24 0.063 
6-MWD (m) ~ 359 ± 110 332 ± 149 <0.001 508 ± 83 496 ± 80 0.107 
Data are mean ± SD; # = COPD (n = 284); ~ = COPD (n = 264); comparator (n = 100); p < 0.05 significant 
difference within groups; FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity; PWV = 
pulse wave velocity; SBP = systolic blood pressure; DBP = diastolic blood pressure; PP = pulse 
pressure; MAP = mean arterial pressure; 6-MWD = six-minute walk distance. 
3.4. Mortality 
After two years, there were 29 deaths (6%) in COPD patients and 2 deaths (1%) in the comparator 
group. The causes of mortality in COPD patients were respiratory (n = 13), cardiovascular (n = 2), 
cancer (n = 6), and other (n = 8). As expected, COPD patients with more severe disease (FEV1 < 50%) 
had greater mortality (n = 17 (10%)) than patients with milder disease (FEV1 > 50%, n = 12, (4%)) (p < 
0.05). 
4. Discussion 
The ARCADE study is the first large prospective longitudinal study of a well-characterized 
cohort of patients with COPD and comparators free from lung disease, with a focus on aPWV as a 
measure of CV risk. The novelty of the ARCADE is the evaluation of the predictive role of aPWV, an 
important indicator of cardiovascular risk [9], which has not been included in other longitudinal 
studies of COPD [21,22]. 
The baseline results of our study demonstrated aortic PWV was greater in the patients than the 
comparators, confirming previous smaller cross-sectional studies [10,23]. The difference was 1.6 m/s, 
which represents a substantial increase in risk in the context of the meta-analysis that showed that a 
1 m/s increase represents a 15% increase in CV risk [9]. Systolic blood pressure and central MAP were 
greater in the COPD patients than in the comparator subjects, which may have been a cause or 
consequence of central vascular stiffness. Increased arterial stiffness and wave reflections, along with 
changes in central haemodynamics, increase left ventricle afterload, enhance the left ventricular 
remodeling process, and also decrease the coronary blood flow, resulting in subendocardial ischemia 
and myocardial injury [12,24,25]. This may result in subclinical CV disease, including left ventricular 
dysfunction, and may be interpreted as premature vascular aging [10,12]. The presence of an 
Medicina 2019, 55, 89 9 of 13 
increased heart rate and lower stroke volume in patients may have been a consequence of cardiac 
dysfunction, but also may have been linked to ventilatory dynamics [26]. 
As expected, lung function was impaired in COPD patients, and patients were more breathless 
and had lower exercise capacity (6-MWD) than comparators. Although biomarkers of systemic 
inflammation, HsCRP, and fibrinogen were greater in the patient group, it is of note that mean 
fibrinogen was within normal values (3.5 g/L) [18], and inflammation was relatively high in 
comparators: This may be explained by the age and presence of subclinical disease in some of the 
comparator subjects. The mean value of HsCRP was substantially elevated in COPD patients, 
indicating high CV risk according to published studies, but was normal in comparators [27]. 
At baseline, in patients and comparators, aPWV was associated with age, MAP, and HR, with 
BMI and the number of comorbidities additionally associated with COPD. The relationship between 
arterial stiffness and age, blood pressure, and HR has been well established and is potentially a 
consequence of increased pulsatile stress promoting vascular remodeling and arterial stiffness [28]. 
There have been conflicting results regarding the relationship between aPWV and lung function and 
inflammation in COPD. One study showed FEV1 was a predictor of aPWV in patients with COPD 
without CV disease, but found that CRP was unrelated [29]. Meanwhile, Sabit et al. have reported 
that aPWV was related to FEV1 and inflammation (interleukin-6) in COPD [10]. It has been suggested 
that vascular inflammation has a role in the development of increased aortic stiffness [30], while BMI 
is associated with metabolic abnormalities/comorbidities, which may explain the contribution of both 
to the model [31]. After two years, the mean change in aPWV in patients and comparators was similar, 
with an increase of almost 0.5 m/s. This is similar to a previous study that showed an annual increase 
of 0.24 m/s in older (>50 years) treated hypertensives [32]. Although the mean increase in aPWV over 
two years was modest, representing a less than 10% increase in CV risk [9], there was a variable 
pattern of change among participants. Nearly 60% of patients and comparators had an increase in 
aPWV, while 39% had a decrease. In neither group was the change correlated to baseline parameters, 
and therefore we were unable to identify particular characteristics of individuals at risk of increased 
aPWV. Previous research has linked changes in PWV to changes in blood pressure, but the lack of 
association in the present study may have been a consequence of the optimization of blood pressure 
when the results were communicated to primary care physicians. 
There was a variable pattern of change over two years in other measures of COPD disease 
severity, including in lung function and 6-MWD. Although the majority of patients with COPD and 
comparators had a decline in lung function and a reduction in 6-MWD, a smaller percentage had an 
increase, and some individuals did not change over two years. This heterogeneity aligns with 
previous longitudinal studies that found that some patients had stable lung function [33] and 6-
MWDs [34] for a number of years. Both patients and comparators showed a decline in lung function 
over two years. A decline in absolute FEV1 (L) would be expected with aging, but the reduction in 
FEV1% predicted likely reflected past exposure to risk factors such as smoking in both groups. The 
reduction in 6-MWD in COPD patients only could be attributed to further reductions in the already 
impaired lung function in COPD patients and the resulting reduction of activity and exercise 
capacity, while the comparators, although losing some lung function, remained within normal limits 
(which may explain their ability to maintain their 6-MWD). 
4.1. Mortality 
At the two-year follow-up, the mortality rate in COPD patients was 6%, with the majority due 
to pulmonary causes. Mortality was greater in COPD patients than in the comparators (1%) and was 
not dissimilar to the 10% mortality reported in the Evaluation of COPD Longitudinally to Identify 
Predictive Surrogate End-points ECLIPSE study, after three years [35]. However, the number of 
deaths of cardiovascular origin was low, which could be explained by the fact that many patients 
were treated with antihypertensives and statins to minimize CV risk factors. Aortic PWV is a 
predictor of CV events and mortality in the general population, but it has shown only a modest 
correlation with lung function in previous studies and was unrelated to FEV1 in this study. This may 
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explain why it would be unlikely to predict lung-related mortality. A longer-term follow-up may yet 
establish its utility as a predictor for CV risk in COPD patients. 
4.2. Strengths and Limitations 
ARCADE is the first large longitudinal study of COPD patients, and includes cardiovascular 
risk factors alongside traditional markers of disease such as lung function, reported exacerbations, 
breathlessness, and exercise capacity. The results were consistent with previous data [33] and are 
likely to be representative of community-dwelling patients with COPD across the spectrum, from 
mild to severe disease (all with spirometric evidence of airway obstruction). The presented data were 
limited by differences in smoking status and overt CV disease between the groups. This demonstrates 
the difficulty in identifying healthy smoker comparators. In order to recruit a representative group 
of patients with COPD, we did not exclude overt CV disease from the COPD group, but to minimize 
the effect of confounders, we excluded other inflammatory states, such as rheumatoid arthritis and 
cancer, in patients and comparators. 
There was a greater loss to follow-up at two years in patients with COPD (43%) than in 
comparators (30%), which may have been a consequence of poorer health (greater exclusions) and an 
inability or unwillingness to return for the second assessment. However, overall participants who 
completed the study were similar in baseline characteristics to those who failed to complete the two-
year assessment. Additional missing data analysis may have provided additional information but 
was beyond the scope of this paper. 
The dropout rate was approximately double that of the ECLIPSE study, which reported 18% 
dropout over two years. However, the ECLIPSE study included follow-ups at three and six months, 
which may have retained participants [21], and a more recent longitudinal study of patients with 
COPD (GOLD B) reported a two-year dropout rate of 63% [36]. 
In epidemiological studies, dropout rates have ranged between 30% and 70%, with high dropout 
associated with smoking and poor socioeconomic status [37]. This may explain the high attrition in 
patients compared to comparators. The mortality data were based on local NHS records, so there was 
potential for some missing data: However, this was minimized, as we attempted to contact all 
participants for the follow-up and received some information from their relatives. 
5. Conclusions 
ARCADE is the first large longitudinal study of CV risk in COPD patients, and it confirmed 
greater arterial stiffness in COPD than comparators. Increased aPWV was observed in COPD patients 
across all age groups, and although the rate of increase was similar to the controls, this suggests early 
or more rapid onset of arterial stiffening in COPD patients. A continued follow-up of ARCADE 
participants will investigate predictors of mortality. 
6. Clinical Trials 
This study is registered at ClinicalTrials.gov with the identification number NCT01656421. 
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